找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: HMG-CoA Reductase Inhibitors; Gerd Schmitz,Michael Torzewski Book 2002 Springer Basel AG 2002 atherosclerosis.cardiovascular.coronary arte

[復(fù)制鏈接]
樓主: 指責(zé)
11#
發(fā)表于 2025-3-23 12:24:01 | 只看該作者
Sterol-regulatory element binding proteins (SREBPs): gene-regulatory target of statin action,of clinical overt cardiovascular complications, like myocardial infarction or stroke, but has almost no effect on angiographically determined luminal diameter of coronary arteries. These, as well as many morphological and molecular studies, have led to a new paradigm of coronary heart disease, i.e.,
12#
發(fā)表于 2025-3-23 15:32:56 | 只看該作者
Cellular effects of HMG-CoA reductase inhibitors on blood cells (monocytes, macrophages, platelets)zed societies. Several important environmental and genetic risk factors are associated with atherosclerosis. Over the past decade, it has become evident that atherosclerosis is not simply an inevitable degenerative consequence of ageing, but rather a chronic inflammatory condition connecting altered
13#
發(fā)表于 2025-3-23 19:59:23 | 只看該作者
Pleiotropic effects of HMG-CoA reductase inhibitors on cells of the vascular wall,ts, cholesterol becomes an important risk factor for cardiovascular disease, as demonstrated in clinical trials from the Framingham Heart Study [.–.] and the Multiple Risk Factor Intervention Trial [., .]. Although dietary cholesterol can contribute to changes in serum cholesterol levels, more than
14#
發(fā)表于 2025-3-23 23:20:05 | 只看該作者
15#
發(fā)表于 2025-3-24 06:02:09 | 只看該作者
16#
發(fā)表于 2025-3-24 09:56:53 | 只看該作者
Cost-effectiveness of statins in primary and secondary prevention of coronary heart disease,e substantial. Consequently, both the primary and secondary prevention of CHD are major objectives of healthcare systems worldwide. Recently, large, multi-centre, clinical trials have demonstrated consistently that these objectives can be achieved though cholesterol-lowering therapy with 3-hydroxy-3
17#
發(fā)表于 2025-3-24 12:00:07 | 只看該作者
18#
發(fā)表于 2025-3-24 15:37:57 | 只看該作者
Milestones in Drug Therapyhttp://image.papertrans.cn/h/image/420250.jpg
19#
發(fā)表于 2025-3-24 21:45:17 | 只看該作者
20#
發(fā)表于 2025-3-25 00:29:56 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-5 05:04
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
南澳县| 辽中县| 永年县| 阿荣旗| 会宁县| 微山县| 吴川市| 海兴县| 社旗县| 栾川县| 黄骅市| 东乡族自治县| 永清县| 黔西县| 重庆市| 云林县| 德钦县| 津市市| 太康县| 乾安县| 德令哈市| 珲春市| 江西省| 竹山县| 巴里| 许昌市| 平阳县| 南开区| 广饶县| 山阳县| 东平县| 南部县| 四平市| 成安县| 吕梁市| 屯昌县| 武冈市| 水富县| 邳州市| 曲水县| 玉溪市|